Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03223792 · ClinicalTrials.gov registry record · NA
Acceptance Of A Partially-Hydrolyzed Infant Formula
A NA study, sponsored by Mead Johnson Nutrition.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT03223792: Completed NA study, sponsored by Mead Johnson Nutrition.
NCT03223792 is a NA study that has completed, run by Mead Johnson Nutrition. The registered enrollment target is 100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03223792, a NA study, has completed, sponsored by Mead Johnson Nutrition.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
This clinical trial will evaluate stool consistency in infants receiving one of two study formulas through a 14-day feeding period.
Interventions
- OTHER Control
- OTHER Investigational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-08-21 |
| Est. Completion | 2018-12-31 |
| Phase | NA |
What the finished NCT03223792 record still lists
NCT03223792 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT03223792 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03223792 about?
NCT03223792 is a clinical study titled "Acceptance Of A Partially-Hydrolyzed Infant Formula". This clinical trial will evaluate stool consistency in infants receiving one of two study formulas through a 14-day feeding period.
What is the current status of trial NCT03223792?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2017-08-21. Estimated completion is 2018-12-31.
What interventions are being tested in trial NCT03223792?
The interventions under investigation include: Control (OTHER), Investigational (OTHER).
Who is sponsoring clinical trial NCT03223792?
This trial is sponsored by Mead Johnson Nutrition, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03223792's enrollment target sits among peer trials
100 840th of 2000 higher than 1,081 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI